NovoRapid

RSS

insulin aspart

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for NovoRapid. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use NovoRapid.

For practical information about using NovoRapid, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 26/02/2019

Authorisation details

Product details
Name
NovoRapid
Agency product number
EMEA/H/C/000258
Active substance
insulin aspart
International non-proprietary name (INN) or common name
insulin aspart
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AB05
Publication details
Marketing-authorisation holder
Novo Nordisk A/S
Revision
29
Date of issue of marketing authorisation valid throughout the European Union
07/09/1999
Contact address
Novo Allé
DK-2880 Bagsværd
Denmark

Product information

26/04/2018 NovoRapid - EMEA/H/C/000258 - II/0121

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

NovoRapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Assessment history

How useful was this page?

Add your rating